Kind Meds (Cannabis Education Blog)

JUNE 27, 2021

Cannabis has had a long, changing history in the United States. Now, as the future of cannabis seems to be promising across the country, there are still many obstacles in the way of medical cannabis becoming legal. At the same time, the pharmaceutical industry has become one of the most powerful businesses in the country.

Pharmaceutical 99

Pharmaceutical Chronic Pain Medicine Nerve Pain 99

NORML

MAY 26, 2020

The delivery of precise doses of THC via an inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions, according to clinical trial data published in the European Journal of Pain. Participants inhaled a precise dose containing either THC (at doses of either 0.5mg or 1mg) or placebo. .”

Clinical Trials 248

Clinical Trials Chronic Pain Cannabinoids Patients 248

Cannabis Law Report

AUGUST 12, 2022

. – August 11, 2022) – MOTAGON, a pharmaceutical company based in Prague and specializing in medical cannabis, has secured a ground-breaking agreement with Europe’s biggest indoor cannabis producer and one of the first cannabis extracts and formulations producers PHCANN INTERNATIONAL. ”

Extraction 52

Extraction Pharmaceutical Patients THC 52

NORML

FEBRUARY 14, 2019

SB1719 allows “registered agents” for those patients physically unable to pick up or receive delivery of their medical cannabis, like those in hospice, assisted living facilities, and those who rely on home healthcare providers. ” Other medical cannabis-related bills are still making their way through the legislature.

Access 199

Access Patients Legislation Medicine 199

Cannabis Law Report

MAY 26, 2023

Multinational operator to supply pharmaceutical-grade CBD extract for European patients TOCANCIPÁ, Colombia, May 25, 2023 (GLOBE NEWSWIRE) — Clever Leaves Holdings Inc.

Pharmaceutical 52

Pharmaceutical Extraction Medicine CBD 52

CannaMD

NOVEMBER 8, 2021

In recognition of this information, a significant but still limited number of Parkinson’s patients have turned to cannabis as a complementary therapy to traditional pharmaceutical options. A survey of current […].

Patients 103

Patients Therapy Pharmaceutical Marijuana 103

Cannabis Law Report

AUGUST 10, 2021

GW was initially granted marketing authorisation for this medicine in the UK in September 2019 as an adjunctive therapy for seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients two years of age and older.

Pharmaceutical 98

Pharmaceutical Treatment Epilepsy Research and Development 98

Cannabis Law Report

NOVEMBER 23, 2020

22 Nov – Blurb… Since 2019, Medicinal Cannabis Clinics has facilitated over 4,000 medical consultations with pre-screened eligible patients and has shown continued month-on-month growth.… … Read More.

Pharmaceutical 59

Pharmaceutical Medicine Patients Cannabis 59

Cannabis Law Report

JUNE 17, 2021

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) raised its full-year 2021 financial guidance based on the acquisition of GW Pharmaceuticals, which was bought on May 5, 2021. regulatory approval, and our new cannabinoid research platform,” said Renée Galá, the chief financial officer of Jazz Pharmaceuticals.

Pharmaceutical 108

Pharmaceutical Clinical Trials Therapy Programs 108

Veriheal

APRIL 7, 2022

While cannabis’ potential to assist with MS has been known for some time now, it’s important to bolster previous findings with expansive research. In a survey of 5,481 MS patients, 47% considered using MMJ, but only 20% spoke with their physician about it. Of the surveyed patients, only 26% reported using it for symptoms.

Patients 98

Patients Treatment Cannabinoids Pharmaceutical 98

Veriheal

FEBRUARY 21, 2023

As medicinal and recreational cannabis legalization continues to sweep across the United States, a recent study paints a concerning portrait of many states denying or restricting medical marijuana (MMJ) access. How Do MMJ Restrictions Affect Patients and Doctors? Many patients take MMJ for more reasons than one.

Access 98

Access Patients Chronic Pain Conditions 98

Cannabis Law Report

AUGUST 27, 2021

Aurora Cannabis Inc.’s ’s (NASDAQ: ACB ) (TSX: ACB ) subsidiary Aurora Germany GmbH and Ethypharm have delivered their initial shipment of cannabis to the French medical cannabis pilot program. If successful, this pilot program could lead to one of the largest regulated medical cannabis markets in Europe.”

Patients 105

Patients Programs Pharmaceutical Compliance 105

Cannabis Law Report

JUNE 23, 2021

COPENHAGEN , June 22, 2021 /PRNewswire/ — Valcon Medical A/S (“Valcon Medical” or the “Company”), Denmark’s leading independent cannabis concentrate and medical formulation provider, received its licensing for the commercial production of cannabis from the Danish Medicines Agency (DKMA) earlier in May 2021.

Pharmaceutical 86

Pharmaceutical Concentrates Extraction Medicine 86

SpeedWeed

APRIL 9, 2021

Nearly two-thirds of Texas medical cannabis users said that weed helped them quit using opioids, benzodiazepines, and other prescription medicines, a new survey reports. From August 11th to October 6th, 2020, researchers asked Texas residents who were using cannabis medicinally to answer an anonymous online survey. percent THC content.

Pharmaceutical 52

Pharmaceutical Chronic Pain Programs Patients 52

MMJ Recs

MAY 15, 2022

This initial MMJ legislation only allowed patients suffering from intractable epilepsy to use cannabis oil. In 2020, the law changed to allow patients with any medical condition to receive a doctor’s recommendation to use and purchase medical marijuana products containing a maximum 10 milligrams of THC.

Patients 52

Patients Marijuana Pharmaceutical Dispensary 52

Cannabis Law Report

DECEMBER 15, 2021

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NASDAQ: CGC ) has entered into an agreement to divest its subsidiary business, C³ Cannabinoid Compound Company GmbH (“C3”), to Dermapharm Holding SE (“Dermapharm”) (WKN: A2GS5D, ISIN: DE000A2GS5D8), a European pharmaceutical company headquartered in Grünwald, Germany.

Pharmaceutical 52

Pharmaceutical Cannabinoids Business Extraction 52

Cannabis Law Report

AUGUST 22, 2021

“The Janus particle solution will allow for time-released and combined therapies to be administered to patients, targeting specific indications. is using cutting-edge delivery technologies to develop safe and effective psychedelic pharmaceutical medicines. ” About Psycheceutical, Inc. Psycheceutical, Inc.

Pharmaceutical 98

Pharmaceutical Medicine Research and Development Therapy 98

The Cannigma

SEPTEMBER 21, 2021

In the world of cannabis, not everyone can be Snoop, Seth Rogen, or Willie Nelson. There are cannabis users, patients, and just everyday fans who may be fans, but don’t make it a big part of their public persona. I also take a chewy (cannabis pill) at bedtime and this has really helped, too.”. 1) Patrick Stewart.

Patients 94

Patients Research and Development Sleep Clinical Trials 94

Cannabis Life Network

OCTOBER 8, 2019

Dissolve Strips ™ (sublingual cannabis wafers) Now Available to Aurora’s Canadian Medical Patients NYSE | TSX: ACB OTC: CTTH EDMONTON and HAMILTON, ON, Oct. The post Aurora Cannabis and CTT Pharmaceutical Launch Sublingual Cannabis Wafers appeared first on Cannabis News | Lifestyle Tips | Expert Opinions | Stocks.

Pharmaceutical 40

Pharmaceutical Cannabis Patients Business 40

Veriheal

FEBRUARY 11, 2021

Cannabis and opioid medications both produce analgesic effects. Researchers who recently published a survey they conducted, wanted to see whether medical cannabis has an effect on the usage of or even possibly replace opioid medications. The Effect of Medical Cannabis on Prescription Opioids. America’s Cannabis Catch-22.

Chronic Pain 87

Chronic Pain Patients Clinical Trials Treatment 87

Cannabis Law Report

JULY 7, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Current TNF-a inhibitors available today, while effective, come with an array of adverse effects and concerns for patients,” said Adam Kaplin, M.D., About MyMD Pharmaceuticals, Inc. Company plans to initiate Phase II trial with a leading academic institution.

Pharmaceutical 105

Pharmaceutical Data Clinical Trials Research and Development 105

Puff Puff Post

MARCH 10, 2020

SOURCE InMed Pharmaceuticals Inc. InMed has conducted preclinical pharmacology studies that suggest CBN in INM-755 may help relieve hallmark EB symptoms, including inflammation and pain, as well potentially restore the integrity of the skin in a subset of EB Simplex patients.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

Cannabis Law Report

AUGUST 17, 2021

reduction in 28-day seizure frequency relative to baseline in tuberous sclerosis complex (TSC) patients (n=23). reduction was observed in focal seizures (n=19), the most common seizure type in TSC patients. Phase 3 planning for TrustTSC trial ongoing with first patient expected to be enrolled in Q4 2021. RADNOR, Pa.–(BUSINESS

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

CannaTech

JANUARY 16, 2019

Thanks to the recent emergence of regulated medical cannabis markets, the success of this versatile plant can be followed from farm to pharma and prescriber to patient, however, the origins of cannabis as medicine cannot be as simply traced as the plant is today from seed to sale. It is not a story about profiting off of people.

Access 89

Access Patients Pharmaceutical Education 89

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. Medical cannabis costs family £4,000 a month to help teenager.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Canna Law Blog

MARCH 6, 2023

Peru has new regulations for the use of medical cannabis, following the issuance of Supreme Decree ( Decreto Supremo ) No. The decree approves the Regulation that Regulates the Medicinal and Therapeutic Use of Cannabis and Its Derivatives ( Reglamento que regula el uso medicinal y terapéutico del cannabis y sus derivados ).

Pharmaceutical 90

Pharmaceutical Patients Environment Cannabis 90

Cannabis Law Report

AUGUST 24, 2021

BALTIMORE–(BUSINESS WIRE)– $MYMD — MyMD Pharmaceuticals, Inc. Thus, there is a great need to develop new and effective therapeutics for treating patients. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 98

Pharmaceutical Clinical Trials Chronic Pain CBD 98

Cannabis Law Report

JUNE 1, 2022

(TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a global leader in medical cannabis throughout Europe and Latin America, announces that it has entered into an agreement to acquire Pharmadrug GmbH from its parent PharmaDrug Inc. CSE:PHRX) (OTC:LMLLF).

Pharmaceutical 52

Pharmaceutical Medicine Extraction Cannabinoids 52

Cannabis Law Report

JUNE 5, 2019

Press Release: Thailand Government Pharmaceutical Organization. The Pharmaceutical Organization, Department of Medical Affairs, signed a joint research on standard quality medical marijuana extracts for patients with chemo-allergic cancer, epilepsy, muscle contraction in patients with deteriorating nerve sheaths.

Pharmaceutical 40

Pharmaceutical Extraction Epilepsy Research and Development 40

NORML

JULY 1, 2019

Three new laws intended to expand patient access to and the therapeutic value of Virginia’s medical cannabis program take effect July 1, 2019. “These bills help ensure that all patients are able to obtain and use the necessary therapeutic doses of their cannabis medicines regardless of location or physical ability.”

Law 257

Law Patients Access Oil 257

Sensi Seeds

NOVEMBER 4, 2021

Sativex by GW Pharmaceuticals is the first fully approved cannabis-based medicine. It is an oral spray containing THC and CBD, used in the treatment of multiple sclerosis (MS) patients. The post Sativex, the Pioneer of Cannabis Medicines appeared first on Sensi Seeds.

Medicine 115

Medicine Pharmaceutical Treatment THC 115

Canna Care Docs

OCTOBER 3, 2023

On top of overwhelming struggles or feelings, patients who have been diagnosed with a terminal illness can face a broad range of both physical and psychological effects. However, many of these pharmaceutical medications can just induce more unpleasant, debilitating effects on those who are ill.

Chronic Pain 105

Chronic Pain Clinical Trials Patients Cannabinoids 105

Cannabis Law Report

SEPTEMBER 22, 2022

List Medicinal Cannabis on the PBS. The Federal Parliament legalised the use of medicinal cannabis products in Australia in February 2016, but access to treatment is still severely limited due to cost, with patients reporting average monthly costs in excess of $300 , or approximately $10 per day. He writes on his website.

Pharmaceutical 52

Pharmaceutical Media Medicine Treatment 52

Cannabis Law Report

JUNE 28, 2021

Pharmaceutical and Medical Cannabis Leaders Zambon GmbH and Adven GmbH will Drive Medical Cannabis Supporting Treatments for Neurological Therapies. The aim of the agreement is to make medical cannabis treatments available to patients, with an initial focus on neurological therapies. billion 1 by 2025.

Access 105

Access Research and Development Pharmaceutical Therapy 105

United Patients Group

APRIL 18, 2023

Introduction The medical cannabis industry is booming. However, there are still many myths about cannabis that persist despite being debunked by medical professionals and researchers alike. Myth: Cannabis is just a drug. Cannabis is a plant. Myth: Cannabis is a gateway to other drugs. Myth: Cannabis is a cure-all.

Research and Development 108

Research and Development Indica Treatment Conditions 108

Cannabis Law Report

DECEMBER 9, 2021

08, 2021 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. In addition to his consulting and directorial responsibilities, he maintains an active research program directed towards improving outcomes for stroke patients. Moreau CEO of Algernon Pharmaceuticals Inc. “We About Algernon Pharmaceuticals Inc. .

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

SpeedWeed

MARCH 30, 2021

THE UK’s first National Health Service patients registry will start collating data from Thursday this week in a significant move for medical cannabis in the country. The development has been welcomed and comes as the nation’s doctors are said to be shifting their cultural stance from viewing ‘cannabis as a dirty word’.

Data 52

Data Patients Clinical Trials Business 52